|Dr. Philip M. Toleikis||Pres, CEO & Director||418.21k||N/A||N/A|
|Mr. David Swetlow C.A., CPA, C.A||Chief Financial Officer||182.28k||N/A||N/A|
|Mr. Douglas Maret||Chief Science Officer||N/A||N/A||N/A|
Sernova Corp., a clinical-stage regenerative medicine therapeutics company, focuses on the development and commercializing of its proprietary Cell Pouch System and associated technologies, including the cell pouch and systemic and/or locally immune protected therapeutic cells and tissues. Its Cell Pouch system is a medical device designed to create a vascularized tissue environment for the transplantation and engraftment of therapeutic cells or tissues for the treatment of chronic diseases, such as diabetes, hemophilia, and hypothyroid disease. The company has a research collaboration with AgeX Therapeutics, Inc. to generate immune-protected universal therapeutic cells. Sernova Corp. was incorporated in 1998 and is headquartered in London, Canada.
Sernova Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.